The Latest

Nyxoah Announces Change to Board of Directors

Nyxoah Announces Change to Board of Directors Mont-Saint-Guibert, Belgium – October 24, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Raymond Cohen resigned as member […]
October 25, 2022

Nyxoah Announces Change to Board of Directors

Mont-Saint-Guibert, Belgium – October 24, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Raymond Cohen resigned as member of the board of directors of the Company effective October 18, 2022.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:
Nyxoah
Loic Moreau, Chief Financial Officer
corporate@nyxoah.com
+32 473 33 19 80

Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com
+1 917 749 1494

Attachment

GlobeNewswire Distribution ID 1000752682

Previous Article

BioCell Technology Expands Global Presence and Trust with Prestigious Halal Certification

Next Article

ZRG Global Talent Advisory Establishes Presence in Dubai

Related Posts

‫”مناهج جديدة”: كيف حافظ الاقتصاد الصيني على مرونته، وانتعش 

بكين، 20 دجنبر/كانون الأول 2022 / PRNewswire / — عقبت بعض وسائل الإعلام رافعة صوتها قائلة إن سيطرة الصين على كوفيد-19 أضرت باقتصاد البلاد. في السنوات الثلاث لمكافحة الوباء، تباطأ معدل النمو الاقتصادي في الصين عند مقارنته بما مضى. ومع ذلك، فهي لا تزال تقود الاقتصادات الرئيسية الأخرى. بناءً على تقديرات الاقتصاديين لمعدل النمو عند […]

‫بيان صحفي: تلتزم ICANN بتدريب سجلات الإنترنت في أفريقيا على أفضل الممارسات

تعهد يضم ICANN مع Partner2Connect في مبادرة بناء القدرات  اسطنبول, 7 يونيو / حزيران 2022 /PRNewswire/ — أعلنت مؤسسة الإنترنت للأسماء والأرقام المخصصة (ICANN) اليوم عن التزامها بتوفير التدريب العملي والأدوات لإعداد 10 سجلات لنطاقات المستوى الأعلى لرموز البلدان الأفريقية (ccTLD) للمنافسة في مجال صناعة النطاقات. وأصدرت ICANN والمنظمات الشريكة لها وهي، الاتحاد الدولي للاتصالات […]

Nyxoah Reports Third Quarter 2023 Financial and Operating Results

Nyxoah Reports Third Quarter 2023 Financial and Operating Results Partners with ResMed Germany to increase OSA awareness and therapy penetration Mont-Saint-Guibert, Belgium – November 8, 2023 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to […]